Observational Study of Oral Premalignancy and Oral Cancer
This observational study aims to better understand oral premalignant (pre-cancerous) and oral cancer tumors. Researchers will look at your clinical information, environmental factors, and genetic makeup to see what increases the risk of developing oral cancer and how it progresses. They will also identify factors that predict how you might respond to treatments like immunotherapy, targeted therapy, surgery, chemotherapy, and radiation, and how these treatments might affect your quality of life. You may be eligible if you are 18 or older and have been diagnosed with, or are suspected of having, oral premalignant or malignant tumors. The study plans to enroll 1000 participants and will follow your symptoms for up to 5 years.
- Study design
- This is an observational study planning to enroll 1000 participants. It is not testing a specific treatment but rather observing patients with oral premalignant or malignant tumors.
- What's involved
- You will have the option to provide biological samples before, during, and after treatment. Functional outcomes of treatment response will also be assessed.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your symptoms will be measured for up to 5 years after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Clinical and Molecular Features of Oral Premalignancy and Oral Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN)up to 5 years
The MDASI-HN is a patient-reported outcome questionnaire designed to measure the severity or burden of systemic and head- and neck-specific symptoms and their interference with or effect on patients' daily functioning (Rosenthal, Mendoza et al. 2007, Cleeland 2016). This 28-item multi-symptom inventory is rated according to the last 24 hours at their worst, with 0 being symptoms not present and 10 being as bad as the patient can imagine. Cronbach alpha reliability ranges from 0.72 to 0.92.